• Main page
• About the journal
• Editorial board
• Subscription
• Information for contributors
• Editorial and Peer Review
• Issues archive
• Authors
• Articles
  • By alphabet
  • By category
• Blogs and comments

The journal is included into The list of leading scientific periodicals.

The journal is included into VINITI database and is registered in Electronic scientific library.

The journal is indexed by SCOPUS, Ulrich's International Periodicals Directory.

EBSCO

https://doi.org/10.14300/mnnc.2024.19009

Studying the level of autoantibodies to the S100B protein dependence on the autoantibodies to neuroreceptors in the blood of schizophrenia patients with various types of emotional-volitional disorders

[Psychiatry]
Mariya Baturina; Oleg Boev; Vladimir Yarovitsky; Eduard Beyer;

The 69 patients with paranoid schizophrenia were examined. Two groups of patients were identified: the first – with a paroxysmal-progredient type of course without a pronounced emotional-volitional defect; the second – with a continuouslyprogredient type of course and a pronounced emotional-volitional defect. Serum levels of autoantibodies (IgG) to S100B protein and dopamine were determined, as well as the content of autoantibodies to neuroreceptors: NMDA receptors (NR1 and NR2A subunits), dopamine receptors of the first and second types (DR1 and DR2). The levels of specific antibodies (IgG) to neuroleptics, that was taken from patients during the examination, were also evaluated. To clarify the dependence of serum concentrations of autoantibodies on the S100B protein (dependent variable), which is considered as a marker of brain dysfunction in diseases of the central nervous system, multiple regression analysis was performed on other indicators recorded in patients. Examination of patients of the first and second groups revealed no differences either in serum levels of autoantibodies to S100B protein, or in levels of autoantibodies to neuroreceptors, dopamine, and neuroleptics. Multiple linear regression analysis confirmed the dependence of the level of autoantibodies to S100B protein on the concentration of autoantibodies to NR2A in patients with schizophrenia without pronounced emotional-volitional disorders. In patients with schizophrenia with severe emotional and volitional disorders, the dependence of the autoantibodies to the S100B protein level on the concentration of autoantibodies to NR2A, as well as on the content of autoantibodies to dopamine and the level of antibodies to neuroleptics was determined.

Download

References:
1. Skripchenko N. V., Shirokova A. S. Neuron-specific enolase and S100 protein as biomarkers of brain damage. Reviev and clinical application. Nejrohirurgiya i Nevrologiya detskogo vozrasta. – Pediatric Neurosurgery and Neurology. 2016;50(4):16-23. (In Russ.).
2. Zhukova N. V., Mavrutenkov V. V., Ushakova G. A. Neurospecific protein S100 – universal biochemical damage marker. Part II. Possibilities and prospects of clinical laboratory diagnostics. Klinicheskaya infektologiya i parazitologiya. – Clinical infectology and parasitology. 2015;1(12):35-49. (In Russ.).
3. Klimenko L. L., Deev A. I., Baskakov I. S., Budanova M. N., Zabirova A. Kh. [et al.]. Neurospecific proteins of S100 family and metal-ligand homeostasis in etiopatogenesis of ischemic stroke: a literature reviev. Mikroelementy v medicine. – Trace Elements in Medicine. 2019;20(4):3-13. (In Russ.). https://doi.org/10.19112/2413-6174-2019-20-4-3-13
4. Steinberg H., Kirkby K. C., Himmerich H. Development of immunoendocrine concept of psychiatric disorders and their therapy. Int. J. Molec. Sci. 2015;16(12):28841-28869. https://doi.org/10.3390/ijms161226136
5. Baturina M. V., Beyer E. V., Zhurbin S. A., Fil’ A. A. The effect of chronic administration of neuroleptics on the blood content of S100 protein and the level of autoantibodies to it in rats. Meditsinskii vestnik Severnogo Kavkaza. – Medical News of North Caucasus.2020;15(4):573-575. (In Russ.). https://doi.org/10.14300/mnnc.2020.15136
6. Baturin V. A., Baturina M. V., Mamtseva G. I., Boev O. I., Yarovitsky V. B., Grudina E. V. Levels of neurotropic autoantibodies in patients with schizophrenia. Medical News of North Caucasus. 2016;11(2):176-178. https://doi.org/10.14300/mnnc.2016.11030
7. Zandi M. S., Irani S. R., Lang B., Waters P., Jones P. B. [et al.]. Disease-relevant autoantibodies in first episode schizophrenia. J. Neurol. 2011;258(4):686-688. https://doi.org/10.1007/s00415-010-5788-9
8. Mayorova M. A., Petrova N. N., Churilov L. P. Schizophrenia as an autoimmune disease: hypotheses and facts. Krymskiy zhurnal eksperimental’noy i klinicheskoy meditsiny. – Crimean Journal of Experimental and Clinical Medicine.2018;8(4):62-76. (In Russ.).
9. Steiner J., Walter M., Glanz W., Sarnyai Z., Bernstein H.-G.[et al.]. Increased prevalence of diverse N-methyl-Daspartate glutamate receptor antibodies in patients with an initial diagnosis of schizophrenia: specific relevance of IgG NR1a antibodies for distinction from N-methylD-aspartate glutamate receptor encephalitis. JAMA Psychiatry. 2013;70(3):271-278. https://doi.org/10.1001/2013.jamapsychiatry.86
10. Lang T. A., Sesik M. Kak opisyvat’ statistiku v medicine. Annotirovannoe rukovodstvo dlya avtorov, redaktorov i recenzentov / pod red. V. P. Leonova. M.: «Prakticheskaya medicina», 2011. (In Russ.).
11. Pavlova O. V., Pavlov K. A., Murashko A. A., Gurina O. I., Shmuklez A. B. NMDA receptors, anti-NMDA receptor antibodies and their role in psychiatric and neuroinflammatory disorders. Molecular medicine. 2021;19(1):3-10. (In Russ.). https://doi.org/10.29296/24999490-2021-01-01
12. Perfilova V. N., Tyurenkov I. N. Glutamate ionotropic receptors: structure, localization, function. Uspekhi fiziologicheskih nauk. – Physics-Uspekhi. 2016;47(1):80-96. (In Russ.).
13. Kalitin K. Yu., Spasov A. A., Mukha O. Yu., Pridvorov G. V., Lipatov V. A. Pharmacological targets and mechanisms of action of antipsychotic agents in the framework of the neurochemical theory of the pathogenesis of schizophrenia. Rossiyskiy fiziologicheskiy zhurnal. – Russian physiological journal. 2021;107(8):927-954. (In Russ.). https://doi.org/10.31857/S0869813921080070
14. Barch D. M., Carter C. S. Amphetamine improves cognitive function in medicated individuals with schizophrenia and in healthy volunteers. Schizophr. Res. 2005;77(1):43-58. https://doi.org/10.1016/j.schres.2004.12.019
15. Vernon A. C., Natesan S., Modo M., Kapur S. Effect of chronic antipsychotic treatment on brain structure: a serial magnetic resonance imaging study with ex vivo and postmortem confirmation. Biol. Psychiatry. 2011;69(10):936-944. https://doi.org/10.1016/j.biopsych.2010.11.010

Keywords: schizophrenia, autoantibodies, S100B protein, NMDA receptors, dopamine receptors